Licensed medicine
A regulator has licensed it for at least one use, in at least one country. That says nothing about uses outside the license.
This page is a stub
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
How strong is the evidence
How far it has climbed
Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.
- Licensed medicine: Teriparatide
A regulator has reviewed the trials and licensed it for a named use.
- Phase 3
Large randomized trials, often thousands of people, against placebo or a standard treatment.
- Phase 2
Mid-sized trials that measure dose against effect in people with the condition.
- Phase 1 and early human studies
First studies in people: safety, and how the body handles it.
- Cells and animals
Laboratory and animal work. An animal result is not a result in people.
- 1,466
- papers on PubMed
- 979
- of them in people
- 221
- randomized trials
- 172
- reviews
A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16
Handling and reconstitution
From powder to a measured sample
The same four steps for any lyophilized vial. Laboratory handling, not use in a person.
1. Read the vial
The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.
2. Add the diluent
A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.
3. Work out the strength
Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.
4. Measure the sample
Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.
The calculator below does the arithmetic and shows its working.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Teriparatide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Teriparatide; no amount here is a recommendation.
Teriparatide: on PubMed
What PubMed held for Teriparatide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 1,466
- papers
- 979
- in humans
- 280
- clinical trials
- 221
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Randomized trialLeder BZ, Tsai JN, Uihlein AV, et al. Lancet (London, England), 2015. PMID 26144908
- Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials
Meta-analysisLi M, Ge Z, Zhang B, et al. Archives of osteoporosis, 2024. PMID 39312040
- Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Randomized trialTsai JN, Uihlein AV, Lee H, et al. Lancet (London, England), 2013. PMID 23683600
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
Randomized trialKendler DL, Marin F, Zerbini CAF, et al. Lancet (London, England), 2018. PMID 29129436
- Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation
ReviewDavis S, Simpson E, Hamilton J, et al. Health technology assessment (Winchester, England), 2020. PMID 32588816
- Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial
Randomized trialSim IW, Borromeo GL, Tsao C, et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. PMID 32614699
- Teriparatide
StudyVall H, Patel P, Parmar M , 2024. PMID 32644674
- Teriparatide
Review, 2012. PMID 31644031
Search used: ("Teriparatide"[ti]). Run it on PubMed
Research links
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Teriparatide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.